Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-marketing confirmatory study of Vicinium for the treatment of non-muscle invasive bladder cancer (NMIBC)

Next Previous
X
Search
Trial Profile

A post-marketing confirmatory study of Vicinium for the treatment of non-muscle invasive bladder cancer (NMIBC)

Status: Suspended
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oportuzumab monatox (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Sesen Bio

    • Most Recent Events

    • 18 Jul 2022 According to Sesen Bio media release, the company plans to voluntarily pause further development of Vicineum in the US.
    • 18 Jul 2022 Status changed from planning to suspended, according to Sesen Bio media release.
    • 05 Nov 2019 According to a Sesen Bio media release, after a discussion of favorable Phase 3 post-hoc analyses with the FDA, this trial is expected to be designed to detect a delayed CR in patients who were non-CRs at the initial 3-month assessment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top